Segui
Ashraf Azzabi
Ashraf Azzabi
Newcastle upon Tyne Hospitals NHS Foundation Trust
Email verificata su nhs.net
Titolo
Citata da
Citata da
Anno
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised …
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
2862022
Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers
EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ...
European urology 76 (6), 831-842, 2019
2502019
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
TJ Iveson, RS Kerr, MP Saunders, J Cassidy, NH Hollander, J Tabernero, ...
The Lancet Oncology 19 (4), 562-578, 2018
2102018
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
A Hughes, P Calvert, A Azzabi, R Plummer, R Johnson, J Rusthoven, ...
Journal of clinical oncology 20 (16), 3533-3544, 2002
1822002
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
EK Bancroft, EC Page, MN Brook, S Thomas, N Taylor, J Pope, J McHugh, ...
The lancet oncology 22 (11), 1618-1631, 2021
752021
A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors
PM Calvert, V O’neill, C Twelves, A Azzabi, A Hughes, C Bale, ...
Proc Am Soc Clin Oncol 20, 108a, 2001
632001
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non …
JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, ...
The lancet oncology 24 (3), 213-227, 2023
622023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two …
G Attard, L Murphy, NW Clarke, A Sachdeva, C Jones, A Hoyle, W Cross, ...
The Lancet Oncology 24 (5), 443-456, 2023
512023
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
MA Batey, JG Wright, A Azzabi, DR Newell, MJ Lind, AH Calvert, ...
European Journal of Cancer 38 (8), 1081-1089, 2002
472002
A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors.
PM Calvert, MS Highley, AN Hughes, ER Plummer, AST Azzabi, ...
Clin Cancer Res 5, 3796S-3796S, 1999
401999
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
T Iveson, KA Boyd, RS Kerr, J Robles-Zurita, MP Saunders, AH Briggs, ...
Health Technology Assessment (Winchester, England) 23 (64), 1, 2019
342019
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
J Robles-Zurita, KA Boyd, AH Briggs, T Iveson, RS Kerr, MP Saunders, ...
British journal of cancer 119 (11), 1332-1338, 2018
292018
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
A Azzabi, AN Hughes, PM Calvert, ER Plummer, R Todd, MJ Griffin, ...
British journal of cancer 92 (6), 1006-1012, 2005
282005
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array
EJ Saunders, T Dadaev, DA Leongamornlert, AAA Olama, S Benlloch, ...
British journal of cancer 114 (8), 945-952, 2016
182016
Optimising radium 223 therapy for metastatic castration-resistant prostate cancer–5-year real-world outcome: Focusing on treatment sequence and quality of life
XY Jiang, S Atkinson, R Pearson, D Leaning, S Cumming, A Burns, ...
Clinical Oncology 32 (10), e177-e187, 2020
152020
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).
AN Hughes, M Lind, AS Azzabi, R Todd, ER Plummer, JP Margetts, ...
Breast Cancer Research and Treatment, 2001
82001
A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.
PM Calvert, V O'Neill, AS Azzabi, AN Hughes, ER Plummer, C Twelves, ...
Clinical Cancer Research, 2000
72000
Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A …
ID Pedley, JA Frew, JM Wilson, AR Abdul Razak, A Azzabi, R McMenemin, ...
Journal of Clinical Oncology 29 (7_suppl), 147-147, 2011
52011
Time from colorectal cancer surgery to adjuvant chemotherapy: post hoc analysis of the SCOT randomized clinical trial
M Gögenur, AW Rosen, T Iveson, RS Kerr, MP Saunders, J Cassidy, ...
JAMA surgery 159 (8), 865-871, 2024
42024
Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study.
RA Pearson, PE Thelwall, J Snell, J McKenna, P Pieniazek, EL Fitzgerald, ...
Journal of Clinical Oncology 34 (2_suppl), 403-403, 2016
42016
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20